ARTL vs. ENSC, LGVN, SNGX, XCUR, THAR, EVOK, REVB, GTBP, ALZN, and PHIO
Should you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Ensysce Biosciences (ENSC), Longeveron (LGVN), Soligenix (SNGX), Exicure (XCUR), Tharimmune (THAR), Evoke Pharma (EVOK), Revelation Biosciences (REVB), GT Biopharma (GTBP), Alzamend Neuro (ALZN), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical preparations" industry.
Artelo Biosciences (NASDAQ:ARTL) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.
0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 6.9% of Artelo Biosciences shares are held by insiders. Comparatively, 39.4% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Artelo Biosciences currently has a consensus target price of $5.00, suggesting a potential upside of 275.94%. Ensysce Biosciences has a consensus target price of $7.00, suggesting a potential upside of 1,144.89%. Given Ensysce Biosciences' higher probable upside, analysts plainly believe Ensysce Biosciences is more favorable than Artelo Biosciences.
Artelo Biosciences received 34 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 72.55% of users gave Artelo Biosciences an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote.
Artelo Biosciences has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.
Artelo Biosciences has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -476.29%. Artelo Biosciences' return on equity of -61.68% beat Ensysce Biosciences' return on equity.
In the previous week, Artelo Biosciences had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 1 mentions for Artelo Biosciences and 0 mentions for Ensysce Biosciences. Artelo Biosciences' average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.
Artelo Biosciences has higher earnings, but lower revenue than Ensysce Biosciences. Artelo Biosciences is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Artelo Biosciences beats Ensysce Biosciences on 9 of the 14 factors compared between the two stocks.
Get Artelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artelo Biosciences Competitors List
Related Companies and Tools
